Voyager Therapeutics

Voyager Therapeutics

Biotechnology
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

$166.4M

Market Cap • 9/28/2026

2013

(13 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,1

P/S

4,8

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,6

EPS

—

Market Cap

Market Cap

166,4M

EV

82,6M

EV/Revenue

2,4

EV/EBITDA

-0,7

EV/EBIT

-0,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-3,9%

Total Yield

-3,9%

Payout

0%

Retained Earnings

-498,3M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

343,8%

Capex/Revenue

2,5%

Capex/D&A

22,2%

Capex/OCF

-0,7%

SBC/OCF

—

% PPE

18,8%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-23,6%

CAGR OCF 5Y

5,9%

Leverage

N.D./EBITDA

0,7

Debt/Equity

0%

Current Ratio

7,5

Quick Ratio

7,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium